Crosstalk between Melatonin Receptor M1 (MTNR1A) and Oxytocin Receptors (OXTR) Expression in the MCF7 Cell Line: A Novel Approach to Understand the Pathophysiology of Breast Cancer

Background: Melatonin's activity is mediated by the melatonin receptors MT1 and MT2. Melatonin promotes apoptosis, regulates pro-survival signaling and tumor metabolism, and suppresses angiogenesis and metastasis. Oxytocin works as a tumor growth regulator by activating the oxytocin receptor, a particular G-coupled transmembrane receptor. Furthermore, an oxytocin-inhibitory impact in mouse and rat breast carcinomas was examined and verified in vivo. Oxytocin secretion follows a circadian rhythm, which is especially noticeable during birth and breastfeeding since most labor phases begin at night when melatonin levels are high.AimIn this study, we will investigate the relationship between melatonin receptors expression M1 MTNR1A and Oxytocin Receptors (OXTR), to understand role of Melatonin Oxytocin correlation in pathogenesis of Breast cancer. Methods: (MCF - 7) breast cancer line and normal breast cell were studied through Real - Time Polymerase Chain Reaction (RT - PCR) to evaluate gene expression of melatonin receptor (MTNR1A) and oxytocin receptors (OXTR) expression and its correlation before and after MTNR1A plasmid transfection. Results: Our results revealed that mRNA MTNR1A expression was significantly low in patient with breast cancer compared to normal subjects also at the same samples the Oxytocin receptors (OXTR) is corelated with melatonin receptors expression as melatonin receptor M1 was high in normal subject the oxytocin Receptors is also was high and low when melatonin receptors was low is liner relationship which confirmed after melatonin receptor up regulated via plasmid transfection and level of apoptotic factors (P53,Bcl2and Caspase 3) Conclusion: Our data indicate that low gene expression of MTNR1A and Oxytocin Receptor (OXTR) in breast cancer tissue. In addition, confirmation of association between MTNR1A and Oxytocin Receptor (OXTR) expression may point to future use of melatonin and Oxytocin Receptor (OXTR) as molecular basis treatment of breast cancer.